+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Ultomiris Drug Market Size, Share & Trends Analysis Report by Indication (PNH, Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder), End-use, Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
Ultomiris Drug Market Size, Share & Trends Analysis Report by Indication (PNH, Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder), End-use, Distribution Channel, and Region with Growth Forecasts, 2025-2030- Product Image
New

Ultomiris Drug Market Size, Share & Trends Analysis Report by Indication (PNH, Myasthenia Gravis, Neuromyelitis Optica Spectrum Disorder), End-use, Distribution Channel, and Region with Growth Forecasts, 2025-2030

  • PDF Icon

    Report

  • 150 Pages
  • May 2025
  • Region: Global
  • Grand View Research
  • ID: 6098031
Description Jump to:
The Ultomiris Drug Market was valued at USD 3.92 billion in 2024, and is projected to reach USD 18.03 billion by 2030, rising at a CAGR of 28.47%. The global Ultomiris (ravulizumab) drug industry is experiencing strong momentum due to the rising demand for long-acting treatments in rare disorders.

Compared to its predecessor, Soliris, the drug's extended dosing interval offers convenience and improved patient compliance. This has increased preference among healthcare providers managing conditions such as paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Alexion reported that over 70% of PNH patients had transitioned to Ultomiris from Soliris in major markets, including the U.S. and EU. The transition from older complement inhibitors to ravulizumab contributes to overall market expansion.

Growth is further fueled by its expanding clinical utility across new indications such as generalized myasthenia gravis (gMG). For instance, in September 2022, Ultomiris received approval from the European Commission to treat adult patients with anti-acetylcholine receptor antibody-positive gMG, strengthening its position in the neurology segment.

The rising incidence of rare autoimmune and hematologic conditions is also a major factor driving demand for Ultomiris. Improved diagnostic tools and updated clinical guidelines have identified eligible patient populations earlier. For instance, in March 2024, the FDA granted priority review to Ultomiris for its potential use in treating neuromyelitis optica spectrum disorder (NMOSD), highlighting its pipeline strength. Strategic marketing efforts and partnerships by AstraZeneca and Alexion have helped expand awareness among clinicians and treatment centers. These combined elements shape a favorable environment for sustained revenue growth through 2030.

Global Ultomiris Drug Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2018 to 2030. For this study, the analyst has segmented the global Ultomiris (ravulizumab) drug market report based on indication, end use, distribution channel, and region:

Indication Outlook (Revenue, USD Million, 2018-2030)

  • Paroxysmal Nocturnal Hemoglobinuria (PNH)
  • Atypical Hemolytic Uremic Syndrome (aHUS)
  • Generalized Myasthenia Gravis (gMG)
  • Neuromyelitis Optica Spectrum Disorder (NMOSD)

End Use Outlook (Revenue, USD Million, 2018-2030)

  • Adult
  • Pediatric

Distribution Channel Outlook (Revenue, USD Million, 2018-2030)

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Regional Outlook (Revenue, USD Million, 2018-2030)

  • North America
  • U.S.
  • Canada
  • Mexico
  • Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
  • Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
  • Latin America
  • Brazil
  • Argentina
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

This report addresses:

  • Market intelligence to enable effective decision-making
  • Market estimates and forecasts from 2018 to 2030
  • Growth opportunities and trend analyses
  • Segment and regional revenue forecasts for market assessment
  • Competition strategy and market share analysis
  • Product innovation listings for you to stay ahead of the curve

Why Should You Buy This Report?

  • Comprehensive Market Analysis: Gain detailed insights into the market across major regions and segments.
  • Competitive Landscape: Explore the market presence of key players.
  • Future Trends: Discover the pivotal trends and drivers shaping the future of the market.
  • Actionable Recommendations: Utilize insights to uncover new revenue streams and guide strategic business decisions.

This product will be delivered within 1-3 business days.

Table of Contents

Chapter 1. Methodology and Scope
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Indication
1.2.2. End Use
1.2.3. Distribution Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
1.5.1. Purchased Database
1.5.2. Internal Database
1.5.3. Secondary Sources
1.5.4. Primary Research
1.6. Information Analysis
1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives
Chapter 2. Executive Summary
2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot
Chapter 3. Ultomiris (Ravulizumab) Drug Market Variables, Trends, & Scope
3.1. Market Lineage Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
3.3.1. Industry Analysis - Porter’s Five Forces Analysis
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat of New Entrants
3.3.1.5. Competitive Rivalry
3.3.2. PESTLE Analysis
3.3.3. Pipeline Analysis
3.3.4. Patent Expiry Analysis
3.3.5. Pricing Analysis
Chapter 4. Ultomiris (Ravulizumab) Drug Market: Indication Business Analysis
4.1. Indication Market Share, 2024 & 2030
4.2. Indication Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Indication, 2018 to 2030 (USD Million)
4.4. Paroxysmal Nocturnal Hemoglobinuria (PNH)
4.4.1. Paroxysmal Nocturnal Hemoglobinuria (PNH) Market, 2018-2030 (USD Million)
4.5. Atypical Hemolytic Uremic Syndrome (aHUS)
4.5.1. Atypical Hemolytic Uremic Syndrome (aHUS) Market, 2018-2030 (USD Million)
4.6. Generalized Myasthenia Gravis (gMG)
4.6.1. Generalized Myasthenia Gravis (gMG) Market, 2018-2030 (USD Million)
4.7. Neuromyelitis Optica Spectrum Disorder (NMOSD)
4.7.1. Neuromyelitis Optica Spectrum Disorder (NMOSD) Market, 2018-2030 (USD Million)
Chapter 5. Ultomiris (Ravulizumab) Drug Market: End Use Business Analysis
5.1. End Use Market Share, 2024 & 2030
5.2. End Use Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by End Use, 2018 to 2030 (USD Million)
5.4. Adult
5.4.1. Adult Market, 2018-2030 (USD Million)
5.5. Pediatric
5.5.1. Pediatric Market, 2018-2030 (USD Million)
Chapter 6. Ultomiris (Ravulizumab) Drug Market: Distribution Channel Business Analysis
6.1. Distribution Channel Market Share, 2024 & 2030
6.2. Distribution Channel Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2018 to 2030 (USD Million)
6.4. Hospital Pharmacies
6.4.1. Hospital Pharmacies Market, 2018-2030 (USD Million)
6.5. Retail Pharmacies
6.5.1. Retail Pharmacies Market, 2018-2030 (USD Million)
6.6. Online Pharmacies
6.6.1. Online Pharmacies Market, 2018-2030 (USD Million)
Chapter 7. Ultomiris (Ravulizumab) Drug Market: Regional Estimates & Trend Analysis
7.1. Regional Market Share Analysis, 2024 & 2030
7.2. Regional Market Dashboard
7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030
7.4. North America
7.4.1. North America Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, By Country, 2018-2030 (USD Million)
7.4.2. U.S.
7.4.2.1. Key Country Dynamics
7.4.2.2. Target Disease Prevalence
7.4.2.3. Regulatory Framework
7.4.2.4. Reimbursement Framework
7.4.2.5. U.S. Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.3. Canada
7.4.3.1. Key Country Dynamics
7.4.3.2. Target Disease Prevalence
7.4.3.3. Regulatory Framework
7.4.3.4. Reimbursement Framework
7.4.3.5. U.S. Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.4.4. Mexico
7.4.4.1. Key Country Dynamics
7.4.4.2. Target Disease Prevalence
7.4.4.3. Regulatory Framework
7.4.4.4. Reimbursement Framework
7.4.4.5. Mexico Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5. Europe
7.5.1. Europe Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.2. UK
7.5.2.1. Key Country Dynamics
7.5.2.2. Target Disease Prevalence
7.5.2.3. Regulatory Framework
7.5.2.4. Reimbursement Framework
7.5.2.5. Uk Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.3. Germany
7.5.3.1. Key Country Dynamics
7.5.3.2. Target Disease Prevalence
7.5.3.3. Regulatory Framework
7.5.3.4. Reimbursement Framework
7.5.3.5. Germany Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.4. France
7.5.4.1. Key Country Dynamics
7.5.4.2. Target Disease Prevalence
7.5.4.3. Regulatory Framework
7.5.4.4. Reimbursement Framework
7.5.4.5. France Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.5. Italy
7.5.5.1. Key Country Dynamics
7.5.5.2. Target Disease Prevalence
7.5.5.3. Regulatory Framework
7.5.5.4. Reimbursement Framework
7.5.5.5. Italy Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.6. Spain
7.5.6.1. Key Country Dynamics
7.5.6.2. Target Disease Prevalence
7.5.6.3. Regulatory Framework
7.5.6.4. Reimbursement Framework
7.5.6.5. Spain Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.7. Denmark
7.5.7.1. Key Country Dynamics
7.5.7.2. Target Disease Prevalence
7.5.7.3. Regulatory Framework
7.5.7.4. Reimbursement Framework
7.5.7.5. Denmark Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.8. Sweden
7.5.8.1. Key Country Dynamics
7.5.8.2. Target Disease Prevalence
7.5.8.3. Regulatory Framework
7.5.8.4. Reimbursement Framework
7.5.8.5. Sweden Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.5.9. Norway
7.5.9.1. Key Country Dynamics
7.5.9.2. Target Disease Prevalence
7.5.9.3. Regulatory Framework
7.5.9.4. Reimbursement Framework
7.5.9.5. Norway Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6. Asia Pacific
7.6.1. Asia Pacific Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.2. Japan
7.6.2.1. Key Country Dynamics
7.6.2.2. Target Disease Prevalence
7.6.2.3. Regulatory Framework
7.6.2.4. Reimbursement Framework
7.6.2.5. Japan Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.3. China
7.6.3.1. Key Country Dynamics
7.6.3.2. Target Disease Prevalence
7.6.3.3. Regulatory Framework
7.6.3.4. Reimbursement Framework
7.6.3.5. China Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.4. India
7.6.4.1. Key Country Dynamics
7.6.4.2. Target Disease Prevalence
7.6.4.3. Regulatory Framework
7.6.4.4. Reimbursement Framework
7.6.4.5. India Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.5. Australia
7.6.5.1. Key Country Dynamics
7.6.5.2. Target Disease Prevalence
7.6.5.3. Regulatory Framework
7.6.5.4. Reimbursement Framework
7.6.5.5. Australia Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.6. South Korea
7.6.6.1. Key Country Dynamics
7.6.6.2. Target Disease Prevalence
7.6.6.3. Regulatory Framework
7.6.6.4. Reimbursement Framework
7.6.6.5. South Korea Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.6.7. Thailand
7.6.7.1. Key Country Dynamics
7.6.7.2. Target Disease Prevalence
7.6.7.3. Regulatory Framework
7.6.7.4. Reimbursement Framework
7.6.7.5. Thailand Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.7. Latin America
7.7.1. Latin America Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.7.2. Brazil
7.7.2.1. Key Country Dynamics
7.7.2.2. Target Disease Prevalence
7.7.2.3. Regulatory Framework
7.7.2.4. Reimbursement Framework
7.7.2.5. Japan Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.7.3. Argentina
7.7.3.1. Key Country Dynamics
7.7.3.2. Target Disease Prevalence
7.7.3.3. Regulatory Framework
7.7.3.4. Reimbursement Framework
7.7.3.5. China Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8. Middle East and Africa
7.8.1. Middle East and Africa Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2017-2030 (USD Million)
7.8.2. South Africa
7.8.2.1. Key Country Dynamics
7.8.2.2. Target Disease Prevalence
7.8.2.3. Regulatory Framework
7.8.2.4. Reimbursement Framework
7.8.2.5. South Africa Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.3. Saudi Arabia
7.8.3.1. Key Country Dynamics
7.8.3.2. Target Disease Prevalence
7.8.3.3. Regulatory Framework
7.8.3.4. Reimbursement Framework
7.8.3.5. Saudi Arabia Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.4. UAE
7.8.4.1. Key Country Dynamics
7.8.4.2. Target Disease Prevalence
7.8.4.3. Regulatory Framework
7.8.4.4. Reimbursement Framework
7.8.4.5. UAE Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
7.8.5. Kuwait
7.8.5.1. Key Country Dynamics
7.8.5.2. Target Disease Prevalence
7.8.5.3. Regulatory Framework
7.8.5.4. Reimbursement Framework
7.8.5.5. Kuwait Ultomiris (Ravulizumab) Drug Market Estimates and Forecasts, 2018-2030 (USD Million)
Chapter 8. Competitive Landscape
8.1. Strategy Mapping
8.2. Company Profiles/Listing
8.2.1. AstraZeneca
8.2.1.1. Overview
8.2.1.2. Financial Performance
8.2.1.3. Product Benchmarking
8.2.1.4. Strategic Initiatives
List of Tables
Table 1 List of secondary sources
Table 2 List of abbreviations
Table 3 Global Ultomiris (ravulizumab) market, by region, 2018-2030 (USD Million)
Table 4 Global Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 5 Global Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 6 Global Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 7 North America Ultomiris (ravulizumab) market, by country, 2018-2030 (USD Million)
Table 8 North America Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 9 North America Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 10 North America Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 11 U.S. Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 12 U.S. Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 13 U.S. Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 14 Canada Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 15 Canada Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 16 Canada Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 17 Mexico Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 18 Mexico Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 19 Mexico Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 20 Europe Ultomiris (ravulizumab) market, by country, 2018-2030 (USD Million)
Table 21 Europe Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 22 Europe Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 23 Europe Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 24 UK Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 25 UK Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 26 UK Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 27 Germany Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 28 Germany Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 29 Germany Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 30 France Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 31 France Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 32 France Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 33 Italy Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 34 Italy Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 35 Italy Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 36 Spain Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 37 Spain Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 38 Spain Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 39 Norway Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 40 Norway Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 41 Norway Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 42 Denmark Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 43 Denmark Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 44 Denmark Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 45 Sweden Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 46 Sweden Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 47 Sweden Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 48 Asia Pacific Ultomiris (ravulizumab) market, by country, 2018-2030 (USD Million)
Table 49 Asia Pacific Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 50 Asia Pacific Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 51 Asia Pacific Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 52 Japan Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 53 Japan Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 54 Japan Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 55 China Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 56 China Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 57 China Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 58 India Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 59 India Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 60 India Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 61 Australia Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 62 Australia Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 63 Australia Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 64 South Korea Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 65 South Korea Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 66 South Korea Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 67 Thailand Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 68 Thailand Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 69 Thailand Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 70 Latin America Ultomiris (ravulizumab) market, by country, 2018-2030 (USD Million)
Table 71 Latin America Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 72 Latin America Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 73 Latin America Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 74 Brazil Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 75 Brazil Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 76 Brazil Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 77 Argentina Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 78 Argentina Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 79 Argentina Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 80 Middle East & Africa Ultomiris (ravulizumab) market, by country, 2018-2030 (USD Million)
Table 81 Middle East & Africa Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 82 Middle East & Africa Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 83 Middle East & Africa Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 84 South Africa Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 85 South Africa Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 86 South Africa Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 87 Saudi Arabia Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 88 Saudi Arabia Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 89 Saudi Arabia Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 90 UAE Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 91 UAE Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 92 UAE Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
Table 93 Kuwait Ultomiris (ravulizumab) market, by indication, 2018-2030 (USD Million)
Table 94 Kuwait Ultomiris (ravulizumab) market, by end use, 2018-2030 (USD Million)
Table 95 Kuwait Ultomiris (ravulizumab) market, by distribution channel, 2018-2030 (USD Million)
List of Figures
Figure 1 Ultomiris (ravulizumab) drug market segmentation
Figure 2 Market research process
Figure 3 Data triangulation techniques
Figure 4 Primary research pattern
Figure 5 Market research approaches
Figure 6 Value-chain-based sizing & forecasting
Figure 7 Market formulation & validation
Figure 8 Market snapshot
Figure 9 Therapeutic approach and application outlook (USD Million)
Figure 10 Competitive landscape
Figure 11 Ultomiris (ravulizumab) drug market dynamics
Figure 12 Ultomiris (ravulizumab) drug market: Porter’s five forces analysis
Figure 13 Ultomiris (ravulizumab) drug market: PESTLE analysis
Figure 14 Indication market, 2018-2030 (USD Million)
Figure 15 Paroxysmal Nocturnal Hemoglobinuria (PNH) market, 2018-2030 (USD Million)
Figure 16 Atypical Hemolytic Uremic Syndrome (aHUS) market, 2018-2030 (USD Million)
Figure 17 Generalized Myasthenia Gravis (gMG) market, 2018-2030 (USD Million)
Figure 18 Neuromyelitis Optica Spectrum Disorder (NMOSD) market, 2018-2030 (USD Million)
Figure 19 End Use market, 2018-2030 (USD Million)
Figure 20 Adult market, 2018-2030 (USD Million)
Figure 21 Pediatric market, 2018-2030 (USD Million)
Figure 22 Distribution Channel market, 2018-2030 (USD Million)
Figure 23 Hospital Pharmacies market, 2018-2030 (USD Million)
Figure 24 Retail Pharmacies market, 2018-2030 (USD Million)
Figure 25 Online Pharmacies market, 2018-2030 (USD Million)
Figure 26 Ultomiris (ravulizumab) market revenue, by region
Figure 27 Regional marketplace: Key takeaways
Figure 28 North America Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 29 U.S. country dynamics
Figure 30 U.S. Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 31 Canada country dynamics
Figure 32 Canada Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 33 Mexico country dynamics
Figure 34 Mexico Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 35 Europe Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 36 UK country dynamics
Figure 37 UK Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 38 Germany country dynamics
Figure 39 Germany Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 40 France country dynamics
Figure 41 France Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 42 Italy country dynamics
Figure 43 Italy Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 44 Spain country dynamics
Figure 45 Spain Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 46 Norway country dynamics
Figure 47 Norway Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 48 Sweden country dynamics
Figure 49 Sweden Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 50 Denmark country dynamics
Figure 51 Denmark Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 52 Asia Pacific Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 53 Japan country dynamics
Figure 54 Japan Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 55 China country dynamics
Figure 56 China Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 57 India country dynamics
Figure 58 India Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 59 Australia country dynamics
Figure 60 Australia Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 61 South Korea country dynamics
Figure 62 South Korea Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 63 Thailand country dynamics
Figure 64 Thailand Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 65 Latin America Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 66 Brazil country dynamics
Figure 67 Brazil Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 68 Argentina country dynamics
Figure 69 Argentina Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 70 MEA Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 71 South Africa country dynamics
Figure 72 South Africa Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 73 Saudi Arabia country dynamics
Figure 74 Saudi Arabia Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 75 UAE country dynamics
Figure 76 UAE Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 77 Kuwait country dynamics
Figure 78 Kuwait Ultomiris (ravulizumab) market, 2018-2030 (USD Million)
Figure 79 Company categorization
Figure 80 Company market position analysis
Figure 81 Strategic framework

Companies Mentioned

The major companies featured in this Ultomiris Drugs market report include
  • AstraZeneca

Table Information

Report AttributeDetails
No. of Pages150
PublishedMay 2025
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 3.92 Billion
Forecasted Market Value ( USD ) by 2030 $ 18.03 Billion
Compound Annual Growth Rate28.4%
Regions CoveredGlobal
No. of Companies Mentioned2

Related Topics

Related Reports

ULTOMIRIS Market Size, Emerging Insight, and Forecast to 2032 - Product Image

ULTOMIRIS Market Size, Emerging Insight, and Forecast to 2032

  • Report
  • 30 Pages
  • Global
From
Diuretics Drugs Market by Drug Class, Indication, Route of Administration, Dosage Form, Distribution Channel - Global Forecast to 2030 - Product Image

Diuretics Drugs Market by Drug Class, Indication, Route of Administration, Dosage Form, Distribution Channel - Global Forecast to 2030

  • Report
  • 183 Pages
  • Global
From
Genitourinary Drugs Market by Indication, Therapeutic Class, Distribution Channel, End User, Route of Administration, Formulation, Sales Model - Global Forecast to 2030 - Product Image

Genitourinary Drugs Market by Indication, Therapeutic Class, Distribution Channel, End User, Route of Administration, Formulation, Sales Model - Global Forecast to 2030

  • Report
  • 199 Pages
  • Global
From
Desmopressin Market by End User, Indication, Product Type, Route of Administration, Distribution Channel - Global Forecast to 2030 - Product Image

Desmopressin Market by End User, Indication, Product Type, Route of Administration, Distribution Channel - Global Forecast to 2030

  • Report
  • 190 Pages
  • Global
From
Overactive Bladder Treatment Market Size, Share & Trends Analysis Report, Type (Anticholinergics, Mirabegron, Neuromodulation, Botox), Disease Type (Idiopathic, Neurogenic), Distribution Channel, Region, and Segment Forecasts, 2024-2030 - Product Image

Overactive Bladder Treatment Market Size, Share & Trends Analysis Report, Type (Anticholinergics, Mirabegron, Neuromodulation, Botox), Disease Type (Idiopathic, Neurogenic), Distribution Channel, Region, and Segment Forecasts, 2024-2030

  • Report
  • 100 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.